Literature DB >> 21993244

RAS oncogenes: weaving a tumorigenic web.

Yuliya Pylayeva-Gupta1, Elda Grabocka, Dafna Bar-Sagi.   

Abstract

RAS proteins are essential components of signalling pathways that emanate from cell surface receptors. Oncogenic activation of these proteins owing to missense mutations is frequently detected in several types of cancer. A wealth of biochemical and genetic studies indicates that RAS proteins control a complex molecular circuitry that consists of a wide array of interconnecting pathways. In this Review, we describe how RAS oncogenes exploit their extensive signalling reach to affect multiple cellular processes that drive tumorigenesis.

Entities:  

Mesh:

Year:  2011        PMID: 21993244      PMCID: PMC3632399          DOI: 10.1038/nrc3106

Source DB:  PubMed          Journal:  Nat Rev Cancer        ISSN: 1474-175X            Impact factor:   60.716


  231 in total

Review 1.  Ras caught in another affair: the exchange factors for Ral.

Authors:  R M Wolthuis; J L Bos
Journal:  Curr Opin Genet Dev       Date:  1999-02       Impact factor: 5.578

2.  Dissection of Ras-dependent signaling pathways controlling aggressive tumor growth of human fibrosarcoma cells: evidence for a potential novel pathway.

Authors:  S Gupta; R Plattner; C J Der; E J Stanbridge
Journal:  Mol Cell Biol       Date:  2000-12       Impact factor: 4.272

3.  Downregulation of the pro-apoptotic protein Bak is required for the ras-induced transformation of intestinal epithelial cells.

Authors:  K Rosen; J Rak; J Jin; R S Kerbel; M J Newman; J Filmus
Journal:  Curr Biol       Date:  1998-12-03       Impact factor: 10.834

4.  Plasmin-dependent and -independent effects of plasminogen activators and inhibitor-1 on ex vivo angiogenesis.

Authors:  S Brodsky; J Chen; A Lee; K Akassoglou; J Norman; M S Goligorsky
Journal:  Am J Physiol Heart Circ Physiol       Date:  2001-10       Impact factor: 4.733

5.  Ras inhibition in glioblastoma down-regulates hypoxia-inducible factor-1alpha, causing glycolysis shutdown and cell death.

Authors:  Roy Blum; Jasmine Jacob-Hirsch; Ninette Amariglio; Gideon Rechavi; Yoel Kloog
Journal:  Cancer Res       Date:  2005-02-01       Impact factor: 12.701

6.  Mechanisms of disease: epithelial-mesenchymal transition--does cellular plasticity fuel neoplastic progression?

Authors:  Eva A Turley; Mandana Veiseh; Derek C Radisky; Mina J Bissell
Journal:  Nat Clin Pract Oncol       Date:  2008-03-18

7.  The Bax subfamily of Bcl2-related proteins is essential for apoptotic signal transduction by c-Jun NH(2)-terminal kinase.

Authors:  Kui Lei; Anjaruwee Nimnual; Wei-Xing Zong; Norman J Kennedy; Richard A Flavell; Craig B Thompson; Dafna Bar-Sagi; Roger J Davis
Journal:  Mol Cell Biol       Date:  2002-07       Impact factor: 4.272

8.  Stimulation of 92-kDa gelatinase B promoter activity by ras is mitogen-activated protein kinase kinase 1-independent and requires multiple transcription factor binding sites including closely spaced PEA3/ets and AP-1 sequences.

Authors:  R Gum; E Lengyel; J Juarez; J H Chen; H Sato; M Seiki; D Boyd
Journal:  J Biol Chem       Date:  1996-05-03       Impact factor: 5.157

Review 9.  Stimulation of angiogenesis by Ras proteins.

Authors:  Onno Kranenburg; Martijn F B G Gebbink; Emile E Voest
Journal:  Biochim Biophys Acta       Date:  2004-03-04

10.  Oncogenic Ras downregulates Rac activity, which leads to increased Rho activity and epithelial-mesenchymal transition.

Authors:  G C Zondag; E E Evers; J P ten Klooster; L Janssen; R A van der Kammen; J G Collard
Journal:  J Cell Biol       Date:  2000-05-15       Impact factor: 10.539

View more
  717 in total

Review 1.  Genetically Engineered Mouse Models of K-Ras-Driven Lung and Pancreatic Tumors: Validation of Therapeutic Targets.

Authors:  Matthias Drosten; Carmen Guerra; Mariano Barbacid
Journal:  Cold Spring Harb Perspect Med       Date:  2018-05-01       Impact factor: 6.915

2.  Persistent ERK/MAPK activation promotes lactotrope differentiation and diminishes tumorigenic phenotype.

Authors:  Allyson Booth; Tammy Trudeau; Crystal Gomez; M Scott Lucia; Arthur Gutierrez-Hartmann
Journal:  Mol Endocrinol       Date:  2014-12

Review 3.  Regulation of TOR by small GTPases.

Authors:  Raúl V Durán; Michael N Hall
Journal:  EMBO Rep       Date:  2012-02-01       Impact factor: 8.807

4.  Regulation of RAS oncogenicity by acetylation.

Authors:  Moon Hee Yang; Seth Nickerson; Eric T Kim; Caroline Liot; Gaelle Laurent; Robert Spang; Mark R Philips; Yibing Shan; David E Shaw; Dafna Bar-Sagi; Marcia C Haigis; Kevin M Haigis
Journal:  Proc Natl Acad Sci U S A       Date:  2012-06-18       Impact factor: 11.205

5.  Unusually long-term responses to vemurafenib in BRAF V600E mutated colon and thyroid cancers followed by the development of rare RAS activating mutations.

Authors:  Tali Ofir Dovrat; Ethan Sokol; Garrett Frampton; Eliya Shachar; Sharon Pelles; Ravit Geva; Ido Wolf
Journal:  Cancer Biol Ther       Date:  2018-07-23       Impact factor: 4.742

6.  R-Ras1 and R-Ras2 Are Essential for Oligodendrocyte Differentiation and Survival for Correct Myelination in the Central Nervous System.

Authors:  Miriam Sanz-Rodriguez; Agnès Gruart; Juan Escudero-Ramirez; Fernando de Castro; José María Delgado-García; Francisco Wandosell; Beatriz Cubelos
Journal:  J Neurosci       Date:  2018-05-02       Impact factor: 6.167

7.  Wild-type RAS: keeping mutant RAS in CHK.

Authors:  Theonie Anastassiadis; Eric J Brown
Journal:  Cancer Cell       Date:  2014-02-10       Impact factor: 31.743

8.  Wild-type H- and N-Ras promote mutant K-Ras-driven tumorigenesis by modulating the DNA damage response.

Authors:  Elda Grabocka; Yuliya Pylayeva-Gupta; Mathew J K Jones; Veronica Lubkov; Eyoel Yemanaberhan; Laura Taylor; Hao Hsuan Jeng; Dafna Bar-Sagi
Journal:  Cancer Cell       Date:  2014-02-10       Impact factor: 31.743

9.  Codon usage regulates human KRAS expression at both transcriptional and translational levels.

Authors:  Jingjing Fu; Yunkun Dang; Christopher Counter; Yi Liu
Journal:  J Biol Chem       Date:  2018-10-01       Impact factor: 5.157

Review 10.  Revisiting the hallmarks of cancer.

Authors:  Yousef Ahmed Fouad; Carmen Aanei
Journal:  Am J Cancer Res       Date:  2017-05-01       Impact factor: 6.166

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.